After FDA Rejects Acadia Dementia Drug, Analysts Lament Lack Of Near-term Stock Drivers
Moderna Analyst Says Biotech Has 'First-To-Market' Potential For Coronavirus Vaccine
After FDA Rejects Acadia Dementia Drug, Analysts Lament Lack Of Near-term Stock Drivers
Moderna Analyst Says Biotech Has 'First-To-Market' Potential For Coronavirus Vaccine
Goldman Sachs Steps To The Sidelines On Crispr Therapeutics
Goldman Sachs Cuts Madrigal Pharma To Neutral Given No Near-Term Catalysts
Salveen Richter Recent News
Goldman Sachs Gets Firm On Solid Biosciences
5 Weed Stocks To Watch In 2018
3 Key Questions For Denali Therapeutics Investors
Spark Therapeutics Lacks Catalysts, Says Goldman Sachs
Goldman Sachs Sees 40% Upside In GW Pharmaceuticals
Goldman: Bluebird Bio Is One Step Closer To A Sickle Cell Cure
What To Expect From GW Pharma's Upcoming Round Of Presentations
Bluebird's Gene Therapy Is Firing On All Cylinders
Following Kite Pharma's Positive Top-Line Data, Focus Turns To Commercial Outlook
GW Pharma Set To Fly High: Goldman Sachs Starts Coverage At Buy, Sees 42% Upside
Seattle Genetics No Longer On Goldman Sachs' Sell List
Goldman Sees Bluebird Bio Preparing For Flight (115% Upside), Adds To 'Conviction Buy' List
Atara Biotherapeutics Has 25% Downside
Bluebird Heading Into 'Catalyst-Rich' Second Half Of The Year
Goldman Sachs Talks Pfizer's Acquisition Deal Of Medivation
Clear Skies For Bluebird Bio To Enter A New Inflection Point
Goldman Sachs Still Bullish On BioMarin Pipeline Despite Kyndrisa Pullout
3 Reasons Goldman Sachs Still Neutral On Intercept Pharma
Bluebird Bio's LentiD 'Hits The Mark'
Goldman Is Buying: Bluebird Bio Off To 'Flying Start'
Goldman On Biotech: Buy Sage, Sell Acorda, Neutral On Dimension
Goldman Sees 2016 'Flight To Quality' In These Biotech Stocks
Avalanche Biotechnologies Buried By Disappointing Data, Downgrades